Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CAIV-T or TIV · 2 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| CAIV-T or TIV | BIOLOGICAL | - |
Inclusion Criteria: * who are aged at least 6 months and less than 72 months of age at the time of enrolment; * who have experienced two or more practitioner attended RTIs\* in the past 12 months (since birth if less than 12 months old); \* RTIs are defined as upper RTIs including (but not limited ...
CAIV-T or TIV is an investigational influenza virus vaccine being studied for the prevention of influenza and respiratory tract infections. It is a monoclonal antibody modality being developed by AstraZeneca PLC. The vaccine has been evaluated in clinical trials involving healthy adults and children.
CAIV-T or TIV is being developed by AstraZeneca PLC, which is publicly traded under the ticker AZN. The company is conducting clinical trials to evaluate the vaccine's safety and immune responses in different populations, including healthy adults and children.
CAIV-T or TIV is in Phase 2 clinical development. While one Phase 2 trial has been completed, the vaccine is still investigational and has not been approved by regulatory authorities. It remains in clinical development for influenza and respiratory tract infections.
CAIV-T or TIV has been studied in clinical trials including NCT00192153, a Phase 2 trial in healthy adults aged 18 and older, and NCT00192205, a Phase 3 trial in children. Both trials are completed, with the Phase 3 trial enrolling 2,200 participants.
CAIV-T and TIV are two different influenza vaccine formulations compared in clinical trials. CAIV-T is a live attenuated vaccine, while TIV is a trivalent inactivated vaccine. They were studied together to compare safety, tolerability, and efficacy in children.